Loading clinical trials...

A Clinical Trial to Investigate the Efficacy of Bragg Apple Cider Vinegar on Blood Glucose Control in a Healthy Adult Population | Clinical Trials | Clareo Health

RECRUITINGNA

A Clinical Trial to Investigate the Efficacy of Bragg Apple Cider Vinegar on Blood Glucose Control in a Healthy Adult Population

A Randomized, Single-blind, Controlled, Cross-over Clinical Trial to Investigate the Efficacy of Bragg Apple Cider Vinegar on Blood Glucose Control in a Healthy Adult Population

NCT07043478•Bragg Live Food Products

View on ClinicalTrials.gov

Summary

The goal of this clinical study is to investigate the efficacy of a Bragg Apple Cider Vinegar (ACV) liquid on postprandial glucose (PPG) excursion compared to a placebo following a standardized acute carbohydrate load. The main question it aims to answer is: Is there a difference in the incremental area under the curve (iAUC) (from 0 - 120 mins following administration) for venous blood glucose between Bragg ACV liquid and placebo following an acute carbohydrate load. Participants will \[describe the main tasks participants will be asked to consume 750 mg of Bragg Apple Cider Vinegar (ACV) liquid or water and undergo a blood draw to measure glucose, insulin, and future analysis markers.

Eligibility

Age

20 - 50 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Males and females 20 - 50 years of age, inclusive 2. Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening
•Or,
•Individuals of child-bearing potential must have a negative screening urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:
•Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)
•Double-barrier method
•Intrauterine devices
•Non-heterosexual lifestyle and agrees to use contraception if planning on changing to heterosexual partner(s)
•Vasectomy of partner at least 6 months prior to screening
•Abstinence and agrees to use contraception if planning on becoming sexually active during the study 3. Subjects with elevated fasting glucose \> 5.6 mmol/L (\> 100 mg/dL) and \< 7.0 mmol/L (\< 126 mg/dL) and/or elevated HbA1c (6.0-6.4%) and two or more of the other following markers associated with metabolic syndrome at screening:
•1. Abdominal obesity: waist circumference \> 102 cm (40 inches) in men and \> 88 cm (35 inches) in women
+3 more criteria

Exclusion Criteria

•1. Individuals who are pregnant, breast feeding, or planning to become pregnant during the study
•2. Allergy, sensitivity or intolerance, preventing consumption of investigational product, placebo, or standardized meal
•3. Poor venous access as assessed by the QI
•4. Current use of prescribed and/or over-the-counter (OTC) medications, supplements, and/or consumption of food/drinks that may impact the glucose metabolism or efficacy of the investigational product (Sections 7.3.1 and 7.3.2)
•5. Unstable metabolic disease or chronic diseases as assessed by the QI
•6. Current or history of any significant diseases of the gastrointestinal tract as assessed by the QI
•7. Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI
•8. Type I or Type II diabetes
•9. Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis
•10. History of or current diagnosis with kidney and/or liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months
+15 more criteria

Locations (1)

KGK Science Inc.

London, Ontario, Canada

Key Dates

Start Date

August 5, 2025

Primary Completion Date

March 1, 2026

Completion Date

March 1, 2026

Last Updated

March 6, 2026

Enrollment

ESTIMATED participants

Conditions

HealthyBlood Glucose

Interventions

Bragg ACV Liquid

OTHER

Placebo

OTHER

Contacts

Marc Moulin, PhD

CONTACT

+12267819094;ext=300 mmoulin@kgkscience.com

Collection of Data and Samples From Healthy Donors for Use in Translational Research

NCT00090662

Healthy Volunteer

View study

RECRUITINGPHASE1/PHASE2

Fecal Microbiota Transplantation for Patients With Autism Spectrum Disorder.

NCT06290258

Autism Spectrum DisorderGastrointestinal Diseases+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 6, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Clinical Trial to Investigate the Efficacy of Bragg Apple Cider Vinegar on Blood Glucose Control in a Healthy Adult Population

Inclusion Criteria

Exclusion Criteria

Collection of Data and Samples From Healthy Donors for Use in Translational Research

Fecal Microbiota Transplantation for Patients With Autism Spectrum Disorder.

A New Portable Device for Non-invasive Ventilatory Support

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

Turkish Validity and Reliability Study of PRevention of Toxic Chemicals in the Environment for Children Tool

A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity